MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. OSCR
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Oscar Health (OSCR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Oscar Health
NYSE•Healthcare•Healthcare Plans
$32.34-0.10(<0.01%)Pre-market
Market Cap
$9.66B
P/E
17.5x
P/S
0.6x
P/B
4.7x

Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

A

How this company scores

ExcellentMetricSide Score: 82/100

Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (16/25).

Profitability16/25
Growth22/25
Balance Sheet & Red Flags21/25
Cash & Earnings Quality23/25
Strengths
Growing revenueRising free cash flowHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.5x5y range 17.5x – 208.1x
P/E 17.5x · below its 5-quarter median

Currently below its 5-quarter median.

P/S · 0.6x5y range 0.1x – 0.9x
P/S 0.6x · above its 19-quarter median

Currently above its 19-quarter median.

P/B · 4.7x5y range 0.6x – 4.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $9.66B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$15.32B
7Q
Q. Revenue
$4.88B
2Q
TTM EBITDA
$672.25M
2Q
TTM Op. Income
$629.72M
2Q
Q. Op. Income
$388.63M
269%
TTM Net Income
$550.74M
2Q
Q. Net Income
$361.81M
258%
EPS
$1.2
235%
Shares Out.
$302.22M
7Q
$15.32B in TTM revenue grew 42.8% YoY, reaching $4.88B last quarter. TTM EBITDA of $672.25M and TTM operating income of $629.72M show growth is flowing through to the bottom line. TTM net income of $550.74M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
8.0%
199%
EBITDA Margin
8.1%
204%
Op. Margin
8.0%
199%
Net Margin
7.4%
193%
Op. margin of 8.0% is up 16.0% YoY — cost efficiency is improving. Net margin at 7.4% and gross margin of 8.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 199% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
17.5x
3Q
P/S Ratio
0.6x
24%
P/B Ratio
4.7x
0%
At 17.5x P/E, the stock trades within typical market levels. P/S of 0.6x and P/B of 4.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$11.23B
3Q
Cash
$4.08B
57%
Long-Term Debt
$431.63M
2Q
Book Value
$2.05B
2Q
D/E Ratio
0.2
3Q
Debt/EBITDA
1.1
With $11.23B in assets and $431.63M in long-term debt, D/E is 0.2and book value is $2.05B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$2.09B
311%
TTM Free Cash Flow
$4.38B
3Q
FCF Margin
28.6%
3Q
FCF / Net Income
8.0
207%
TTM FCF of $4.38B on $2.09B in operating cash flow. The FCF / Net Income ratio of 8.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 4.7x
· above its 20-quarter median

Currently above its 20-quarter median.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Share Dilution

Red Flag

Shares outstanding increased 24.3% — significant dilution, likely from stock compensation or capital raises.